Company: XOMAP
Filing Date: 2025-11-13
Form Type: SC TO-T/A
Source: 0001193125-25-278820
Chunk: 1

Company: XOMA Royalty Corp
Filing Date: 2025-11-13
Form: SC TO-T/A
Chunk 1
---
 purchase all of the issued and outstanding common shares, with a nominal value of €0.12 per share
(“”), in the capital of LAVA Therapeutics N.V., a public limited liability company (naamlozevennootschap) organized under the laws of the Netherlands, having its corporate seat (statutairezetel) in Utrecht, the Netherlands, registered with the Dutch trade register under number 65335740 (“”), for a price per Share of (i) $1.04 (the “”), and (ii) one non-transferable contractual contingent value right (“”) for each Share, which shall represent the right to receive potential payments, in cash, described in, and subject to and in accordance
with the terms and conditions of, the CVR Agreement, subject to any applicable tax withholding and without interest (such amount, the “,” and together with the Cash Amount, the “”),
all upon the terms and subject to the conditions described in the Amended and Restated Offer to Purchase, dated October 17, 2025 (together with any subsequent amendments or supplements thereto, the “”) filed
herewith and in the related Letter of Transmittal, copies of which are attached hereto as exhibits (a)(1)(A) and (a)(1)(B), respectively. The Offer is being made pursuant to the Share Purchase Agreement, dated as of August 3, 2025 (together
with any amendments or supplements thereto, the “”), among LAVA and Purchaser, a copy of which is filed as Exhibit (d)(1) hereto and incorporated herein by reference with respect to Items 4 through 11 of this
Schedule TO.

Except as otherwise set forth in this Amendment, all terms of the Offer and all other disclosures set forth in the
Schedule TO and the Exhibits thereto remain unchanged and are hereby expressly incorporated into this Amendment by reference. This Amendment should be read together with the Schedule TO. Capitalized terms used and not otherwise defined in
this Amendment shall have the meanings assigned to such terms in the Offer to Purchase.

The Schedule TO is hereby amended and
supplemented as follows:

ITEMS 1 THROUGH 9 AND 11

The Offer to Purchase and Items 1 through 9 and 11 of the Schedule TO, to the extent such Items incorporate by reference the information
contained in the Offer to Purchase, are hereby amended and supplemented to include the following:

“Initial Expiration of the Offer